YIH
CAPR icon

Y-Intercept (HK)’s Capricor Therapeutics CAPR Stock Holding History

Y-Intercept (HK)’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,537
Closed -$133K – 1436
2024
Q1 		$133K Buy
19,537
+9,274
+90% +$44.8K 0.01% 1235
2023
Q4 		$50.2K Buy
+10,263
New +$33.4K ﹤0.01% 1161

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Y-Intercept (HK)'s CAPR Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Capricor Therapeutics (CAPR) in Q2 2024, closing a stake of 19,537 shares — an estimated $133K sold.

Y-Intercept (HK) first reported a position in CAPR in Q4 2023 and held it in 2 quarters. The position peaked at $133K in Q1 2024. 61 funds tracked by Wall St. Rank hold CAPR as of Q2 2024.

  • Y-Intercept (HK) reported no remaining Capricor Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 19,537 Capricor Therapeutics shares in Q2 2024, an estimated $133K.
  • Y-Intercept (HK) first reported a position in Capricor Therapeutics in Q4 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Capricor Therapeutics position peaked at $133K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.